Mr. Annis entered the biotech community in 1996 at Icogen Inc., where he worked with a team to pilot and characterize protein therapeutics for the treatment of disabling haplo-insufficiencies. This work has led to IND’s (Investigational New Drug applications), clinical trials, worldwide patents, and market ready therapeutics. Joining Rosetta/Merck & Co., Inc., in 2004 he became involved in the development and industrialization of Lentiviral mediated shRNA HTS screening capabilities within the Molecular Profiling franchise. Annis has also developed several HTS siRNA assays across multiple disease areas that were utilized for biological network validation, compound enhancement/suppression and target discovery.